Each month, subscribers to The Formulary® Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.
Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The December 2001 Formulary monograph topics are budesonide modified-release capsules, tenofovir disoproxil fumarate, pegfilgrastim, fulvestrant, and etonogestrol/ethinyl estradiol vaginal ring. The DUE is on budesonide modified-release capsules.
EgrieJ.C., BrowneJ.K.Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer.2001; 84(Suppl 1): 3–10.
6.
BriddellR.Novel erythropoiesis stimulating protein (NESP) is at least equivalent in promoting in vitro human burst forming unit-erythroid (BFU-E) derived colony formation from peripheral blood (PB) compared with recombinant human erythropoietin (rHuEPO)[abstract]. Exp Hematol.1999; 27(suppl): 91.
7.
EgrieJ.C.Novel erythropoiesis stimulating protein (NESP) has a longer serum half-life and greater in vivo biological activity than recombinant human erythropoietin (rHuEPO) [abstract]. Blood.1997; 90(10, suppl): 56a.
8.
CookeK.Anemia of chronic disease (ACD) in a rodent model is similar to human ACD and can be alleviated by Aranesp treatment [abstract]. Blood.2000; 96(11 pt 1): 20.
9.
HartleyC.Novel erythropoiesis stimulating protein (NESP) can correct the anemia of cisplatin-induced renal damage with a single weekly injection while repeated dosing with rHuEPO is required to obtain the same effect [abstract]. Exp Hematol.1999; 27(suppl): 91.
10.
HartleyC.Infrequent administration of novel erythropoiesis stimulating protein (NESP) to support erythropoiesis in a murine model of multicycle chemo/radiotherapy [abstract]. Blood.2000; 96(11 pt 2): 1274.
11.
AkahoriH.The effect of novel erythropoiesis stimulating protein (NESP) on anemia induced by renal failure in rats [abstract]. Exp Hematol.1998; 26: 766.
12.
HartleyC.Pre-treatment with novel erythropoiesis stimulating protein (NESP) prevents chemotherapy induced anemia in mice [abstract]. Blood.1999; 94(10, suppl): 51a.
13.
AkahoriH.The effect of novel erythropoiesis stimulating protein (NESP) on anemia in a rat model of cis-platin-induced renal failure [abstract]. Blood.1999; 94(10, suppl): 194a.
14.
MacdougallI.C.Pharmacokinetics of IV and SC novel erythropoiesis stimulating protein (NESP) and IV epoetin alfa (EPO) in CAPD patients [abstract]. Kidney Int.1999; 55: 2103.
15.
MacdougallI.C.Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol.1999; 10: 2392–5.
16.
AllonM.The pharmacokinetics of novel erythropoiesis stimulating protein (NESP) following chronic intravenous administration is time- and dose-linear [abstract]. J Am Soc Nephrol.2000; 11(suppl): A1308.
17.
TsengL.The pharmacokinetics of Aranesp in oncology patients undergoing multicycle chemotherapy [abstract]. Blood.2000; 96(11 pt 2): 4379.
18.
GlaspyJ.Novel erythropoiesis stimulating protein (NESP) exhibits a prolonged serum half life (T1/2) in oncology patients (Pts) [abstract 210]. American Society of Clinical Oncology 36th Annual Meeting. New Orleans, LA; May 2000.
19.
LernerG.R.The pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in pediatric patients with chronic renal failure (CRF) or end-stage renal disease [abstract]. J Am Soc Nephrol.2000; 11(suppl): A1479.
20.
CoyneD.W.Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at reduced dose frequency compared with recombinant-human erythropoietin (r-HuEPO) [abstract]. J Am Soc Nephrol.2000; 11(suppl): A1380.
21.
LocatelliF.Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int.2001; 60: 741–7.
22.
LocatelliF.Novel erythropoiesis stimulating protein (NESP) administered subcutaneously corrects anemia in subjects with chronic renal insufficiency (CRI) when administered at a reduced dose frequency compared with recombinant-human erythropoietin (r-HuEPO) [abstract]. J Am Soc Nephrol.2000; 11(suppl): A1486.
23.
SuranyiM.Novel erythropoiesis stimulating protein (NESP) administered once every other week corrects anemia in patients with chronic renal insufficiency (CRI) [abstract]. Am J Kidney Dis.2001; 37(4): 84.
24.
MacdougallI.C., UK NESP Study Group. Novel erythropoiesis stimulating protein (NESP) administered subcutaneously (SC) for the treatment of renal anaemia [abstract]. Kidney Int.1999; 55: 2560–1.
25.
MacdougallI.C.Novel erythropoiesis stimulating protein (NESP) for the treatment of renal anaemia [abstract]. J Am Soc Nephrol.1999; 10(suppl): A1317.
26.
NissensonA.R.Novel erythropoiesis stimulating protein (NESP) safety maintains hemoglobin concentration levels in hemodialysis patients as effectively as r-HuEPO when administered once weekly [abstract]. J Am Soc Nephrol.2000; 11(suppl): A1326.
27.
VanrenterghemY.Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin (Hgb) in ESRD patients when administered once weekly or once every other week [abstract]. J Am Soc Nephrol.1999; 10(suppl): A1365.
28.
GrafH.Novel erythropoiesis stimulating protein (NESP) effectively maintains hemoglobin (Hgb) when administered at a reduced dose frequency compared with recombinant human erythropoietin (r-HuEPO) in dialysis patients [abstract]. J Am Soc Nephrol.2000; 11(suppl): A1317.
29.
GlaspyJ.A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer.2001; 84(Suppl 1): 17–23.
30.
GlaspyJ.A.Randomized, active-controlled, phase 1/2, dose-escalation study of NESP administered weekly and every 2 weeks in patients with solid tumors [abstract 1546]. American Society of Clinical Oncology 37th Annual Meeting. San Francisco; May 2001.
31.
KotasekD.Randomized, double-blind, placebo controlled, phase I/II dose finding study of Aranesp administered once every three weeks in solid tumor patients [abstract]. Blood.2000; 96(11 pt 1): 1268.
32.
GlaspyJ.Open-label, phase I/II dose-escalation study of Aranesp in patients with chronic anemia of cancer [abstract]. Blood.2000; 96(11 pt 2): 4370.
33.
SmithR.E.Jr,Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer.2001; 84(Suppl 1): 24–30.
34.
SmithR.E.Open-label, phase I/II dose escalation study of NESP in patients with chronic anemia of cancer [abstract 1574]. American Society of Clinical Oncology 37th Annual Meeting. San Francisco; May 2001.
35.
HedenusM.A randomized, blinded, placebo-controlled, phase II, dose-finding study of novel erythropoiesis stimulating protein (NESP) in patients with lymphoproliferative malignancies [abstract 1569]. American Society of Clinical Oncology 37th Annual Meeting. San Francisco; May 2001.
36.
PirkerR.A phase 3, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum treatment for lung cancer [abstract 1572]. American Society of Clinical Oncology 37th Annual Meeting. San Francisco; May 2001.
37.
FaustE.A phase III, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (Aranesp) in patients undergoing platinum-treatment for lung cancer [abstract 1293]. American Society of Clinical Oncology 37th Annual Meeting. San Francisco; May 2001.
38.
BesarabA.The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med.1998; 339: 584–90.
39.
The NESP Usage Guidelines Group.Practical guidelines for the use of NESP in treating renal anemia. Nephrol Dial Transplant.2001; 16(Suppl 3): 22–8.
